Adverse Gastrointestinal Effects of Alendronate Versus Risedronate in Osteoporosis: A Systematic Review and Meta-analysis.

Ann Afr MedMay 14, 2026 (epub)
Clinical ResearchGastroenterologyInternal Medicine (General)

Mahmoud Ismail Nouh, Hala Albuti, Mohammed Hasosah et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis compared gastrointestinal (GI) adverse effects of alendronate and risedronate in osteoporosis treatment, analyzing data from six randomized controlled trials involving 4,151 participants. The incidence of GI adverse effects was 20.19% for alendronate and 18.30% for risedronate, with no significant difference (RR: 1.11; 95% CI: 0.86-1.42; P < 0.44).

Key findings

  • The incidence of GI adverse effects was 20.19% for alendronate and 18.30% for risedronate.
  • No significant difference in GI adverse effects between alendronate and risedronate (RR: 1.11; 95% CI: 0.86-1.42; P < 0.44).
  • Switching from alendronate to risedronate may lower GI side effects, despite the lack of statistical significance.

Why it matters

Understanding the gastrointestinal safety profiles of bisphosphonates is crucial for optimizing osteoporosis management. Clinicians can consider these findings when prescribing treatment to minimize adverse effects.

Source

PubMed · PMID 42138626

Published in Ann Afr Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.